AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

ABBV Quantitative Stock Analysis May 20, 2025 — 09:06 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Pim van Vliet.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The stock's fall snapped a three-day winning streak.

This comprehensive analysis delves into AbbVie’s current position, future prospects, and the factors shaping its stock performance. Company Overview and Recent Performance ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie’s stock price remained relatively ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...